Alizyme is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focussed on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory bowel disease and mucositis, a serious side effect of cancer therapy.
Alizyme takes drug product candidates from an early stage into clinical development with the objective of demonstrating their efficacy in patients and providing a comprehensive data package to support the further development and commercialisation of the drug. Alizyme owns the intellectual property rights to all four drug products currently in clinical trials and has an exclusive worldwide licence to the COLAL™ drug delivery system.
At a suitable stage Alizyme aims to license its products to pharmaceutical companies that have the ability to complete the clinical development of the product, to gain approval from the regulatory authorities and to successfully market the product.
Alizyme has developed its business with a high emphasis on outsourcing, controlled by its core management team and specialist advisors. Rather than establish its own laboratories and development facilities, it has worked with collaborators and service providers such as contract research organisations. This has the benefit of allowing Alizyme to focus its investment onto its development programmes in a cost effective way.
| Contact Details: |
| Granta Park, Great Abingdon |
| Cambridge |
| Cambridgeshire |
| CB1 6GX |
| United Kingdom |
| Tel: | 44 1223 896000 |
| Fax: | 44 1223 896001 |
| Email: | info@alizyme.co.uk |
| WWW: | www.alizyme.co.uk/
|
|
Loading...
|
Recent Publications by Alizyme Therapeutics Limited: |  |
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.
AIMS: To assess the efficacy, pharmacodynamics, safety and tolerability of... | 18th February, 2009
| Alizyme Therapeutics Ltd, Great Abington, Cambridge, UK.
| Br J Clin Pharmacol. 2009 Mar;67(3):309-15. Epub 2008 Sep 19.
DOI Direct Link |
Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.
BACKGROUND AND OBJECTIVE: Renzapride (ATL-1251), a novel benzamide, is... | 7th May, 2008
| Alizyme Therapeutics
| Drugs R D. 2008;9(1):37-63.
|
The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.
The cardiac safety of renzapride, a novel benzamide currently under... | 27th February, 2008
| Alizyme Therapeutics
| J Int Med Res. 2007 Nov-Dec;35(6):848-66.
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 767 times since April 2007, the link to the organisation's website has been followed 167 times
Recent Search Terms used to find this page: alizyme therapeutics ltd cambridge uk | Alizyme Therapeutics limited | alizyme therapeutics ltd | Alizyme Therapeutics Ltd | alizyme mucositis | alizyme therapeutics ltd | alizyme therapeutics | Alizyme Therapeutics Limited ABINGDON | alizyme therapeutics ltd | synthesis of benzoxazinone derivatives 2009 | .
Search for more companies in Cambridge
Search for more companies in Cambridgeshire
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Alizyme Therapeutics Limited
